Testing a new drug for metastatic prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer has spread to other parts of your body and has gotten worse despite hormone treatment.
- Your PSA level is at least 1 ng/mL.
- You are on hormone therapy (or have had your testicles removed) to keep your testosterone level very low.
- You are well enough to carry out daily activities (ECOG score 0 or 1).
- You are willing to provide a tumor sample (from a past biopsy or a new one).
- You have not had certain prior treatments for prostate cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.
This study tests a new experimental drug (AZD8359) designed to target prostate cancer cells in men whose cancer has progressed despite previous treatments. The drug works by directing immune cells to attack cancer cells.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This trial is for men with metastatic prostate cancer that has gotten worse despite treatment. It tests a new drug called AZD9750, given alone or with other cancer drugs, to see if it is safe and works well.
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
This trial tests a new drug that delivers radiation directly to cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.